Strides Pharma Science Bangalore facility gets USFDA inspection closure
The flagship facility in Bangalore is the largest manufacturing facility for the company, with the capability to produce finished dosage formulation products across multiple dosage formats, including tablets, capsules, ointments, creams, and liquids.
Bangalore: Strides Pharma Science Ltd has announced that the U.S. Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) in relation to the inspection of the Company’s flagship facility in Bangalore, India.
The Company’s flagship facility was inspected by the USFDA between December 5 and 9, 2022, and a form 483 listing three inspectional observations was issued.
Based on the Company’s response to the observations and subsequent commitments, the USFDA has classified the outcome of this inspection as VAI (voluntary action indicated), and the EIR states that the inspection is closed.
The flagship facility in Bangalore is the largest manufacturing facility for the company, with the capability to produce finished dosage formulation products across multiple dosage formats, including tablets, capsules, ointments, creams, and liquids. The facility services the key regulated markets of the US, Europe, and Australia.
Read also: Strides Pharma Science successfully concludes WHO inspection at Puducherry facility
Strides is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor‐funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi), and the United States (New York).
Read also: Strides Pharma Science biologics arm gets USFDA EIR for Bengaluru facility
